Pharmacological targeting of endoplasmic reticulum stress in disease

SJ Marciniak, JE Chambers, D Ron - Nature reviews Drug discovery, 2022 - nature.com
The accumulation of misfolded proteins in the endoplasmic reticulum (ER) leads to ER
stress, resulting in activation of the unfolded protein response (UPR) that aims to restore …

Cystic fibrosis: a review

T Ong, BW Ramsey - Jama, 2023 - jamanetwork.com
Importance Cystic fibrosis, a genetic disorder defined by variants in the cystic fibrosis
transmembrane conductance regulator (CFTR) gene, affects more than 30 000 individuals in …

[HTML][HTML] Worldwide rates of diagnosis and effective treatment for cystic fibrosis

J Guo, A Garratt, A Hill - Journal of Cystic Fibrosis, 2022 - Elsevier
Background Time has seen management for Cystic Fibrosis (CF) advance drastically, most
recently in the development of the disease-modifying triple combination therapy …

Molecular structures reveal synergistic rescue of Δ508 CFTR by Trikafta modulators

K Fiedorczuk, J Chen - Science, 2022 - science.org
The predominant mutation causing cystic fibrosis, a deletion of phenylalanine 508 (Δ508) in
the cystic fibrosis transmembrane conductance regulator (CFTR), leads to severe defects in …

Mechanism of CFTR correction by type I folding correctors

K Fiedorczuk, J Chen - Cell, 2022 - cell.com
Small molecule chaperones have been exploited as therapeutics for the hundreds of
diseases caused by protein misfolding. The most successful examples are the CFTR …

Folding correctors can restore CFTR posttranslational folding landscape by allosteric domain–domain coupling

N Soya, H Xu, A Roldan, Z Yang, H Ye, F Jiang… - Nature …, 2023 - nature.com
The folding/misfolding and pharmacological rescue of multidomain ATP-binding cassette
(ABC) C-subfamily transporters, essential for organismal health, remain incompletely …

Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescription

E Dreano, PR Burgel, A Hatton… - European …, 2023 - Eur Respiratory Soc
Background Around 20% of people with cystic fibrosis (pwCF) do not have access to the
triple combination elexacaftor/tezacaftor/ivacaftor (ETI) in Europe because they do not carry …

CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis

JL Taylor-Cousar, PD Robinson, M Shteinberg… - The Lancet, 2023 - thelancet.com
Following discovery of the cystic fibrosis transmembrane conductance regulator (CFTR)
gene in 1989 and subsequent elucidation of the varied CFTR protein abnormalities that …

Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment

CA Shaughnessy, PL Zeitlin, PE Bratcher - Scientific reports, 2021 - nature.com
Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance
regulator (CFTR), which lead to early death due to progressive lung disease. The …

Pyrazole-containing pharmaceuticals: target, pharmacological activity, and their SAR studies

G Li, Y Cheng, C Han, C Song, N Huang… - RSC Medicinal …, 2022 - pubs.rsc.org
Pyrazole is a five-membered heterocycle bearing two adjacent nitrogen atoms. Both
pharmaceutical agents and natural products with pyrazole as a nucleus have exhibited a …